VIMTALABS638.50

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹1,416 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
31/12/2024
Inventory Days (DIO)0.00111.97118.30118.30
Receivable Days (DSO)100.9191.7599.7799.77
Payable Days (DPO)57.0771.4739.4339.86
Cash Conversion Cycle (days)43.84132.25178.64178.21
Working Capital Turnover3.632.993.073.25
Asset Turnover0.910.880.800.80
Cash Conversion (CFO/Net Income)1.431.831.481.48
CFO/EBITDA0.740.930.700.70
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.